CA3024532C - Pyrimidine derivative, method for preparing same and use thereof in medicine - Google Patents

Pyrimidine derivative, method for preparing same and use thereof in medicine Download PDF

Info

Publication number
CA3024532C
CA3024532C CA3024532A CA3024532A CA3024532C CA 3024532 C CA3024532 C CA 3024532C CA 3024532 A CA3024532 A CA 3024532A CA 3024532 A CA3024532 A CA 3024532A CA 3024532 C CA3024532 C CA 3024532C
Authority
CA
Canada
Prior art keywords
compound
tert
membered
pharmaceutically acceptable
tautomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3024532A
Other languages
English (en)
French (fr)
Other versions
CA3024532A1 (en
Inventor
Lei Chen
Dongliang Guan
Hua Bai
Jun Gou
Weifeng Zhao
Zhongli WANG
Long Ling
Yutao Ma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CA3024532A1 publication Critical patent/CA3024532A1/en
Application granted granted Critical
Publication of CA3024532C publication Critical patent/CA3024532C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3024532A 2016-05-20 2017-05-19 Pyrimidine derivative, method for preparing same and use thereof in medicine Active CA3024532C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610341444 2016-05-20
CN201610341444.0 2016-05-20
PCT/CN2017/085135 WO2017198221A1 (zh) 2016-05-20 2017-05-19 嘧啶类衍生物、其制备方法和其在医药上的用途

Publications (2)

Publication Number Publication Date
CA3024532A1 CA3024532A1 (en) 2017-11-23
CA3024532C true CA3024532C (en) 2021-02-09

Family

ID=60324797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3024532A Active CA3024532C (en) 2016-05-20 2017-05-19 Pyrimidine derivative, method for preparing same and use thereof in medicine

Country Status (7)

Country Link
US (4) US10654836B2 (enExample)
EP (1) EP3459952B1 (enExample)
JP (1) JP6667014B2 (enExample)
CN (1) CN108884097B (enExample)
CA (1) CA3024532C (enExample)
TW (1) TWI669300B (enExample)
WO (1) WO2017198221A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
CN107660200B (zh) 2015-04-14 2022-01-11 卫材R&D管理有限公司 结晶fgfr4抑制剂化合物和其用途
JP7372740B2 (ja) 2016-05-10 2023-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
CN108822048A (zh) * 2018-07-23 2018-11-16 上海昌肽生物科技有限公司 4-(4-乙基-4,7二氮杂螺环[3,3]辛基)-2-硝基苯胺的合成工艺
TWI723480B (zh) 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
CN115490670A (zh) * 2021-06-17 2022-12-20 浙江海正药业股份有限公司 Fgfr4选择性抑制剂的盐及其制备方法和用途
CN115504965A (zh) 2021-06-23 2022-12-23 浙江海正药业股份有限公司 嘧啶类衍生物的晶型及其制备方法
CN116947825B (zh) * 2022-04-14 2025-11-28 浙江海正药业股份有限公司 Fgfr4选择性抑制剂化合物的晶型及其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
AR079257A1 (es) * 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CN102250065B (zh) * 2011-05-20 2015-05-13 浙江海正药业股份有限公司 取代的三嗪苯脲衍生物及其用途
UA114501C2 (uk) * 2012-02-28 2017-06-26 Астеллас Фарма Інк. Азотовмісна ароматична гетероциклічна сполука
KR20150037207A (ko) * 2013-09-30 2015-04-08 한미약품 주식회사 Fms 키나아제 저해 활성을 갖는 피리미딘 화합물
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
CN104860891B (zh) * 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物

Also Published As

Publication number Publication date
US11827625B2 (en) 2023-11-28
EP3459952B1 (en) 2022-01-05
US12358898B2 (en) 2025-07-15
JP6667014B2 (ja) 2020-03-18
US20190161476A1 (en) 2019-05-30
CN108884097B (zh) 2021-05-28
EP3459952A4 (en) 2020-01-15
WO2017198221A1 (zh) 2017-11-23
US20240018130A1 (en) 2024-01-18
TWI669300B (zh) 2019-08-21
US20210221797A1 (en) 2021-07-22
CA3024532A1 (en) 2017-11-23
TW201741303A (zh) 2017-12-01
US10654836B2 (en) 2020-05-19
US11001572B2 (en) 2021-05-11
JP2019519512A (ja) 2019-07-11
US20200207745A1 (en) 2020-07-02
CN108884097A (zh) 2018-11-23
EP3459952A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
US11827625B2 (en) Pyrimidine derivative, method for preparing same and use thereof in medicine
KR102776114B1 (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
AU2015252654B2 (en) Polyfluorinated compounds acting as Bruton's tyrosine kinase inhibitors
CA2641744C (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
IL266510A (en) History of aminopyrimidine, their preparation and pharmaceutical preparations containing them
KR101850282B1 (ko) 단백질 키나아제 저해제로 유용한 헤테로아릴아민 유도체
KR102388312B1 (ko) 아미노피리미딘 화합물, 이의 제조방법 및 용도
JP2010536869A (ja) ナフチルピリミジン、ナフチルピラジンおよびナフチルピリダジン類似体、ならびにＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用
CA2489452C (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2021261002A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
KR20200134179A (ko) N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN119095839A (zh) 作为Mas相关G蛋白受体X2的调节剂和相关产物的喹啉衍生物
WO2022212818A1 (en) 1,2,4-triazolo[4,3-a]pyridine derivatives as negative allosteric modulators of metabotropic glutamate receptor 2
CN111499613A (zh) N-甲酰胺衍生物、其制备方法及其在医药上的用途
CN110317202A (zh) 氰基吡咯并杂芳基类衍生物、其制备方法及其在医药上的应用
RU2718915C2 (ru) Производные пиримидина в качестве ингибиторов киназ и их терапевтические применения
CA3100095C (en) Indoline-1-carboxamide compound, preparation method therefor and medical use thereof
WO2024158745A1 (en) Inhibitors of lrrk2
EP4673440A1 (en) Inhibitors of lrrk2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181116

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421